# US 2001/0025379 A1 · Cyclin-dependent kinase inhibitors as plant growth regulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025379 A1
- Document ID: US20010025379A1
- Status: Published application
- Kind: A1
- Application number: 09/733,507
- Filed: 2000-12-08
- Published: 2001-09-27
- Earliest claimed: 1998-06-08
- Assignees: Her Majessty the Queen in right of Canada, as represented by the Minister of Natural Resources; University of Saskatchewan; The Natural Research Council of Canada
- Inventors: Hong Wang; Larry C. Fowke; William L. Crosby
- Web page: https://patentgrep.com/patent/US20010025379A1

## CPC

- C12N 15/8261: {with agronomic (input) traits, e.g. crop yield}
- C07K 14/415: from plants
- Y02A 40/146: Genetically Modified [GMO] plants, e.g. transgenic plants
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods for using cyclin-dependent kinase (CDK) inhibitor genes, or anti-sense constructs complementary to such genes, to modify the growth and development of plant cells and organs are disclosed. Also provided are methods of modifying the development of plant cells and plants by transforming plant cells with nucleic acids encoding cyclin-dependent kinase inhibitor polypeptides, or anti-sense constructs complementary to such nucleic acids, to produce transformed plant cells, and then culturing the plant cells or regenerating a plant under conditions wherein the cyclin-dependent kinase inhibitor, or the anti-sense construct, is expressed. A variety of CDK inhibitor genes, and corresponding anti-sense constructs, are disclosed for use in a variety of plants. The nucleic acid encoding the cyclin-dependent kinase inhibitor may be operably linked to a tissue-specific promoter. Other provided aspects are modified transgenic plants and plant tissues. Also provided are methods of identifying nucleic acids that encode cyclin-dependent kinase inhibitors that are active in plants to modify the development of the plant.

## Claims

### Claim 1

A method of modifying development of a plant comprising transforming a plant cell with a nucleic acid encoding a plant cyclin-dependent kinase inhibitor polypeptide to produce a transformed plant cell; and, growing the transformed plant cell or progeny of the transformed plant cell to produce a transformed plant under conditions wherein the plant cyclin-dependent kinase inhibitor polypeptide is expressed in a proliferative tissue of the transformed plant to inhibit development of a differentiated tissue in the plant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor is homologous to ICK1, ICK2, ICN2, ICN6 or ICN7.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor is selected from a group consisting of ICK1, ICK2, ICN2, ICN6 and ICN7.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cyclin-dependent kinase inhibitor polypeptide is 70% identical, when optimally aligned, to ICK1, ICK2, ICN2, ICN6 or ICN7.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cyclin-dependent kinase inhibitor polypeptide is selected from a group consisting of ICK1, ICK2, ICN2, ICN6 and ICN7.

### Claim 6 (depends on 1)

The method of claim 1, wherein the plant is a member of the Cruciferae family.

### Claim 7 (depends on 1)

The method of claim 1, wherein the plant is a member of the Brassica genus.

### Claim 8 (depends on 1)

The method of claim 1, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide is operably linked to a constitutive promoter.

### Claim 9 (depends on 1)

The method of claim 1, wherein the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide is operably linked to a tissue-specific promoter.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tissue-specific promoter is at least 90% identical, when optimally aligned, to an AP3 promoter.

### Claim 11 (depends on 9)

The method of claim 9, wherein the tissue-specific promoter is the AP3 promoter.

### Claim 12 (depends on 9)

The method of claim 9, wherein the tissue-specific promoter mediates expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide in petal or stamen primordia.

### Claim 13 (depends on 1)

The method of claim 1 wherein the development of the tissue in the plant is modified so that the plant is male sterile.

### Claim 14 (depends on 1)

The method of claim 1 wherein the development of the tissue in the plant is modified so that petals on the transformed plant are altered or absent.

### Claim 15 (depends on 1)

A transgenic plant comprising an expressible heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide capable of inhibiting a cyclin-dependent kinase, wherein the heterologous nucleic acid is introduced into the transgenic plant, or an ancestor of the transgenic plant by the method of claim 1.

### Claim 16

A method of modifying development of a plant, wherein the plant comprises a nucleic acid encoding a cyclin-dependent kinase inhibitor polypeptide, comprising transforming a plant cell with an anti-sense coding sequence complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide, to produce a transformed plant cell; and, growing the transformed plant cell or progeny of the transformed plant cell to produce a transformed plant under conditions wherein the anti-sense nucleic acid is transcribed in a proliferative tissue of the transformed plant to inhibit expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide in the proliferative tissue of the transformed plant, to promote growth of a differentiated tissue in the plant.

### Claim 17 (depends on 16)

A transgenic plant having a recombinant genome comprising:
a nucleic acid encoding a cyclin-dependent kinase inhibitor; and,
a heterologous anti-sense coding sequence complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor;
wherein the heterologous anti-sense coding sequence is introduced into the plant, or an ancestor of the plant, by the method of claim 16.

### Claim 18

A transgenic plant having a recombinant genome comprising a heterologous nucleic acid encoding a cyclin-dependent kinase inhibitor that is expressed in a proliferative tissue of the transformed plant to inhibit development of a differentiated tissue in the plant.

### Claim 19

A transgenic plant having a recombinant genome comprising:
a nucleic acid encoding a cyclin-dependent kinase inhibitor; and,
a heterologous anti-sense coding sequence complementary to the nucleic acid encoding the cyclin-dependent kinase inhibitor;
wherein the anti-sense coding sequence is transcribed in a proliferative tissue of the transformed plant to inhibit expression of the nucleic acid encoding the cyclin-dependent kinase inhibitor polypeptide in the proliferative tissue of the transformed plant, to promote growth of a differentiated tissue in the plant.

### Claim 20 (depends on 18)

A transgenic plant tissue derived from the transgenic plant of claim 18.

### Claim 21 (depends on 20)

The plant tissue of claim 20 wherein the tissue is selected from the group consisting of a seed and a flower.

### Claim 22 (depends on 18)

A method of growing the transgenic plant of claim 18, comprising growing the plant under conditions so that the cyclin-dependent kinase inhibitor polypeptide is expressed in a proliferative tissue of the transformed plant to inhibit development of a differentiated tissue in the plant.

### Claim 23 (depends on 19)

A method of growing the transgenic plant of claim 19, comprising growing the plant under conditions so that the anti-sense nucleic acid is transcribed in a proliferative tissue of the plant to inhibit the expression of the cyclin-dependent kinase inhibitor in the proliferative tissue to promote development of a differentiated tissue in the plant.

### Claim 24

An isolated nucleic acid encoding a plant cyclin-dependent kinase inhibitor, wherein the nucleic acid is at least 90% identical, when optimally aligned, to a nucleic acid selected from a group consisting of ICK2, ICN2, ICN6 and ICN7.

### Claim 25 (depends on 24)

The nucleic acid of claim 24, wherein the nucleic acid is selected from a group consisting of ICK2, ICN2, ICN6 and ICN7.

### Claim 26 (depends on 24)

An isolated plant cyclin-dependent kinase inhibitor polypeptide encoded by the nucleic acid of claim 24.

### Claim 27

A method of modifying development of a plant comprising transforming a plant cell with a nucleic acid encoding a plant cyclin-dependent kinase inhibitor polypeptide to produce a transformed plant cell; and, growing the transformed plant cell or progeny of the transformed plant cell to produce a transformed plant under conditions wherein the plant cyclin-dependent kinase inhibitor polypeptide is expressed in a proliferative tissue of the transformed plant to change the ploidy of a differentiated tissue in the plant.
